Newscast – Page 82 – media

Researchers’ wearable measures force athletes put on tendons

Researchers from the University of Wisconsin-Madison have detailed a wearable device that can better measure muscle-tendon tension during certain activities, such as walking or running.
- Source: MobiHealthNews
- 2,281
- April 30, 2018
digital health medical device Researches
Multiple sclerosis drug could reduce painful side effects of common cancer treatment

Researchers from the Saint Louis University School of Medicine have discovered why many multiple myeloma patients experience severe pain when treated with the anticancer drug bortezomib. The study, which will be published April 27 in the Journal of Experimental Medicine, suggests that a drug already approved to treat multiple sclerosis could mitigate this effect, allowing myeloma patients to successfully complete their treatment and relieving the pain of myeloma survivors.
- Source: medicalxpress.
- 458
- April 28, 2018
multiple myeloma Researches
GSK reports Q1 sales decline

GlaxoSmithKline has booked a 2 percent dip in revenues for the first quarter to £7.2 billion, after results were hit by a “significant currency impact” and lower sales of prescription drugs. Profit after tax fell 38 percent to £759 million, while earnings per share dropped to 11.2p from 21.4p a year ago.
- Source: pharmatimes
- 494
- April 28, 2018
Company Insights GSK
CAR-T therapy could be available to NHS patients this year

NHS England chief executive Simon Stevens has indicated that chimeric antigen receptor T-cell therapy (CAR-T) could be available on the NHS this year, offering eligible patients a ‘ground-breaking’ approach to treating cancer.
- Source: pharmatimes
- 5,100
- April 28, 2018
cancer NHS T cell therapy
Specialty Vaccines for Overlooked Infectious Diseases–Challenges and Opportunities

Developing specialty vaccines for emerging and overlooked infectious diseases is a challenging and rewarding enterprise with specific opportunities and problems. Large companies have not historically prioritized this area and instead have focused on the development and commercialization of routine vaccines and vaccines for diseases with more significant global markets.
- Source: fiercepharma
- 480
- April 28, 2018
Researches vaccines
mHealth Program Uses Smartphones to Monitor Medication Adherence

Video directly observed therapy (VDOT), an mHealth platform in which patients use an app to record themselves taking medications, can improve adherence and reduce costs, according to a new study.
- Source: mHealth Intelligence
- 914
- April 28, 2018
mHealth Researches
In a medical first, drugs have reversed an inherited disorder in the womb

Doctors in Germany successfully treated twins in utero using a biotech drug, pointing to a new way to eliminate disease.
- Source: TechnologyReview
- 415
- April 28, 2018
digital health medtech Researches
Foundation Medicine’s New Liquid Biopsy Assay Granted Breakthrough Device Designation by U.S. Food and Drug Administration

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the U.S. Food and Drug Administration (FDA) granted a Breakthrough Device designation (formerly Expedited Access Pathway program) for its new liquid biopsy assay, which is an expanded version of its FoundationACT® assay. The new assay will include more than 70 genes and genomic biomarkers for microsatellite instability (MSI) and blood tumor mutational burden (bTMB). If approved, this test could be the first FDA-approved liquid biopsy assay to incorporate multiple companion diagnostics (CDx) and multiple biomarkers to inform the use of targeted oncology therapies, including immunotherapies.
- Source: nvestors.foundationmedicine
- 585
- April 27, 2018
FDA liquid biopsy assay microsatellite instability
Once-daily Trelegy Ellipta gains expanded indication in the US for the treatment of patients with COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved an expanded indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’), which means this medicine can now be used by US physicians to treat a broader population of chronic obstructive pulmonary disease (COPD) patients with airflow limitation or who have experienced an acute worsening of respiratory symptoms.
- Source: us.gsk
- 643
- April 27, 2018
Company Insights COPD FDA GSK
AbbVie Submits Biologics License Application to U.S. FDA for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis

In clinical studies, more than half of patients receiving risankizumab achieved complete skin clearance (PASI 100) at one year (52 weeks) (1) The Biologics License Application is supported by four Phase 3 studies of more than 2,000 patients with moderate to severe plaque psoriasis (1-3) Risankizumab is an investigational compound designed to selectively inhibit IL-23 by binding to its p19 subunit and is being evaluated for the potential to deliver long-term skin clearance for psoriasis patients with 12-week dosing (4)
- Source: prnewswire
- 644
- April 27, 2018
AbbVie FDA New Approvals plaque psoriasis

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.